Page 1

EX - 99.1 2 a20210803mdxg2q2021pressre.htm EX - 99.1 EXHIBIT 99.1 MIMEDX Announces Second Quarter 2021 Operating and Financial Results Second Quarter Net Sales Increase 27 % to $ 68.2 million Versus Q2 2020 On Track to Deliver Topline Results for Late - Stage Musculoskeletal Pipeline in Late Summer Company to Host Conference Call on August 4 , 2021 , at 8:30 AM ET MARIETTA , Ga . , August 3 , 2021 -- MiMedx Group , Inc. ( Nasdaq : MDXG ) ( " MIMEDX " or the " Company " ) , an industry leader in utilizing amniotic tissue as a platform for regenerative medicine , today announced the filing of its second quarter 2021 Form 10 - Q for the period ended June 30 , 2021 . Timothy R. Wright , MIMEDX Chief Executive Officer , commented , “ Our expanded commercial team is working aggressively toward the goal of achieving above - market growth for our Advanced Wound Care business , and executing on multiple initiatives that reinforce the differentiation of our products and convey the clinical and economic value of our brands . As the only data - driven amniotic tissue allograft to have complete national commercial coverage for the treatment of Diabetic Foot Ulcers , we continue to leverage our expansive reimbursement coverage and invest in medical education programs that are designed to raise awareness on the appropriate and timely use of our Advanced Wound Care products . It is imperative that we continue to grow this base business to support patients in need . " Mr. Wright continued , “ I applaud the team for their efforts to exercise strong leadership and exceptional customer service throughout the end of the period of Enforcement Discretion . Our proactive and continued dialogue with the U.S. Food and Drug Administration ( FDA ) enabled us to mitigate customer disruption , dispel misinformation , and partner with customers throughout the transition . Backed by years of clinical , tissue engineering , and manufacturing knowledge about the science of amniotic tissue , MIMEDX is well - positioned to advance into a more rigorously regulated biologics pathway , and we are making significant progress on the critical steps necessary for a complete and potentially successful Biologics License Application ( BLA ) . We remain on track to share topline results for our Plantar Fasciitis and Knee Osteoarthritis programs by late summer and review these data with the FDA . " Second Quarter 2021 and Recent Operating Highlights : • • • • . Announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine ( WFIRM ) to develop and advance scientific evidence in support of safe and effective clinical therapies Received regulatory approval to commercialize PURION® processed EPIFIX® in Japan Announced the publication of a peer - reviewed study in the Journal of Investigative Dermatology Innovations addressing the potential benefit of MIMEDX PURION® processed dehydrated Human Amnion / Chorion Membrane ( dHACM ) to combat complications stemming from excessive fibrosis , a pathological process central to a number of serious unmet medical needs Added to the Russell 2000Ⓡ and Russell 3000® Indexes Notified by the FDA that the Company's Investigational New Drug ( IND ) for the use of AMNIOFIX® Injectable ( mdHACM ) in Surgical Incisions was accepted as filed